Hong D S, Deeg H J
Program in Transplantation Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Med Oncol. 1994;11(2):63-8. doi: 10.1007/BF02988832.
Classically hemopoietic stem cells to be used for transplantation or autologous reinfusion have been harvested from the bone marrow which has remained the major source of stem cells for allogeneic transplantation. However, pluripotent stem cells also circulate in peripheral blood under physiological conditions and can be "mobilized" to appear in very large numbers in peripheral blood by treatment with cytotoxic chemotherapy, hemopoietic growth factors, or both. These cells are now being used widely for autologous stem cell support. They have the advantage of very rapid hemopoietic reconstitution, thereby shortening the posttransplant period of pancytopenia. Fetal liver cells, another classic source of stem cells, are currently used only infrequently. However, there is a growing interest in the use of umbilical cord blood which is rich in stem cells and easily accessible. Cord blood stem cells have been used successfully for pediatric transplants even across major histocompatibility barriers. Technology has been developed which may permit sufficient in vitro expansion so that these cells can also be used for transplants in adults. Furthermore, there is evidence that these cells may be preferable to marrow or even mobilised peripheral blood stem cells for the purpose of gene transfer.
传统上,用于移植或自体回输的造血干细胞是从骨髓中采集的,骨髓一直是同种异体移植干细胞的主要来源。然而,多能干细胞在生理条件下也会在外周血中循环,并且可以通过细胞毒性化疗、造血生长因子或两者联合治疗“动员”,使其在外周血中大量出现。这些细胞现在被广泛用于自体干细胞支持。它们具有造血重建非常迅速的优势,从而缩短移植后全血细胞减少的时期。胎儿肝细胞是另一种经典的干细胞来源,目前使用较少。然而,人们对使用富含干细胞且易于获取的脐带血的兴趣日益浓厚。脐带血干细胞已成功用于儿科移植,甚至跨越主要组织相容性屏障。已经开发出的技术可能允许进行足够的体外扩增,以便这些细胞也可用于成人移植。此外,有证据表明,就基因转移而言,这些细胞可能比骨髓甚至动员的外周血干细胞更具优势。